The life sciences company is dedicated to creating highly effective and differentiated treatments for cystic fibrosis. Using over a decade of research on the genetic mutations associated with the disease, Sionna Therapeutics is focused on developing first-in-class small molecules that target a unique area with the potential to fully normalize CFTR function, providing best-in-class efficacy and long-term benefits for the vast majority of people living with cystic fibrosis.